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Pulmonary administration of biomimetic nanoparticles loaded with antigen may represent 
an effective strategy to directly modulate adaptive immune responses in the respiratory 
tract. Depending on the design, virosomes may not only serve as biomimetic antigen 
carriers but are also endowed with intrinsic immune-stimulatory properties. We designed 
fluorescently labeled influenza-derived virosomes and liposome controls coupled to 
the model antigen ovalbumin to investigate uptake, phenotype changes, and antigen 
processing by antigen-presenting cells exposed to such particles in different respira-
tory tract compartments. Both virosomes and liposomes were captured by pulmonary 
macrophages and dendritic cells alike and induced activation in particle-bearing cells by 
upregulation of costimulatory markers such as CD40, CD80, CD86, PD-L1, PD-L2, and 
ICOS-L. Though antigen processing and accumulation of both coupled and soluble anti-
gen was similar between virosomes and liposomes, only ovalbumin-coupled virosomes 
generated a strong antigen-specific CD4+ T cell proliferation. Pulmonary administrated 
antigen-coupled virosomes therefore effectively induced adaptive immune responses 
and may be utilized in novel preventive or therapeutic approaches in the respiratory tract.
Keywords: immune modulation, virosomes, liposomes, virus-like particle, respiratory tract, dendritic cell, 
macrophage
inTrODUcTiOn
Immune modulation in the lung may represent a direct approach for treating respiratory disorders 
such as allergic asthma (1, 2), given that the respiratory tract is readily accessible, making it an ideal 
target for non-invasive treatments. A dense network of dendritic cells (DCs) ensures mucosal uptake 
and transport of antigen to lymph nodes for presentation and activation of T cells, as previous studies 
showed that free antigen is insufficient to induce a strong immune reaction in the respiratory tract (3, 4). 
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In recent years, biomedical nanoparticles for targeted delivery of 
antigen for vaccinations have been developed (5–7), but to date 
there is insufficient understanding on how such nanoparticles 
interact with immune cells in the lung.
Biomimetic nanoparticles such as virosomes and liposomes 
have already been approved for human use due to their advan-
tageous safety profile and tolerance (8–10). Virosomes may 
be generated from all enveloped viruses, such as influenza, 
respiratory syncytial virus (RSV), herpes simplex, human 
immunodeficiency, rubella, measles, Sendai, West Nile, dengue, 
yellow fever, or Zika virus (11–16). Virosomes derived from 
influenza are spherical nanocarriers containing constituents 
from the influenza virus envelope, hemagglutinin (HA), and 
neuraminidase (NA) that are incorporated into the phospho-
lipid bilayer. In contrast to liposomes, virosomes are endowed 
by intrinsic immunogenic properties (11, 12), functioning both 
as carrier and adjuvant, as they are able to deliver antigens and 
stimulate immune cells simultaneously (17, 18). Incorporated 
HA not only provides additional adjuvant function to virosomes 
but also promotes a rapid cellular uptake by endocytosis (19). 
HA binds to sialic acid residues that are abundantly expressed 
on DCs and macrophages (20), thereby triggering highly efficient 
receptor-mediated uptake.
Within the respiratory tract, immunogens may encounter 
various immune cells such as macrophages, DCs, and B cells (21). 
For modulating immune responses, DCs are the preferred target 
as these are the most potent antigen-presenting cells (APCs). 
After antigen uptake, DCs undergo so-called maturation, endow-
ing them with the capacity to effectively stimulate CD4+ T cells 
by presenting processed antigen in the context of MHC class 
II to the T  cell receptor. During this maturation process, DCs 
upregulate surface expression of costimulatory molecules such 
as CD40, CD80, and CD86 ensuring strong and specific CD4+ 
T  cell stimulation. DCs are therefore able to take up, process, 
and present antigen to naïve CD4+ T cells in the lung-draining 
lymph nodes (LDLNs), thereby regulating T cell responses in the 
respiratory tract. Viral infection of epithelial cells is first detected 
by a germline-encoded set of sensors expressed by epithelial 
cells and innate immune cells [i.e., pattern recognition recep-
tors (PRRs)], which recognize pathogen-associated molecular 
patterns (PAMPs) originating from the invading viral pathogens 
[reviewed in Ref. (22)]. PRR sensors include the toll-like recep-
tors, RNA-sensing RIG-I-like receptors, such as retinoic acid-
inducible gene I (RIG-I), melanoma differentiation-associated 
protein 5, and C-type lectin receptors. Despite extensive research, 
no interaction of influenza virosomes devoid of genetic material 
was reported to date with PRRs.
In the lung, two major types of migratory conventional DCs 
have been described, CD11b+CD103− and CD11b−CD103+ DCs 
(23, 24). CD11b−CD103+ DCs are localized within the airway 
epithelium, through which they extend their dendrites to sample 
antigen from the airway lumen (23), whereas CD11b+CD103− 
DCs are found in the lamina propria and submucosa of con-
ducting airways and sample antigens that have penetrated the 
epithelium (25, 26).
We have previously shown that both virosomes and liposomes 
are captured by monocyte-derived DCs and monocyte-derived 
macrophages in a human triple coculture model, but uptake of 
virosomes occurred faster, with more virosomes taken up than 
liposomes in DC monocultures (27). In the current study, we 
hypothesized that in an in vivo-mouse model, virosomes would 
also constitute an ideal carrier with immune-stimulatory proper-
ties that would enable to modulate adaptive pulmonary immune 
responses. We tested this by applying empty virosomes or 
liposomes or coupled to OVA with PBS as control intranasally to 
naïve BALB/c mice and analyzing uptake and phenotypic changes 
in various respiratory tract compartments. In addition, intracel-
lular processing of antigen and downstream OVA-specific CD4+ 
T cell activation in LDLN was analyzed. To our knowledge, this 
study represents the first in its field to demonstrate the potential 
of virosomes for enhanced T cell stimulation in an in vivo model 
for pulmonary application, which highlights these particles as a 
promising antigen carrier for immune modulation in the respira-
tory tract.
MaTerials anD MeThODs
Virosome and liposome Formulation
Influenza virosomes and liposomes were formulated and 
characterized as previously described in detail (27). Virosome 
or liposome formulations were either conjugated to the model 
protein OVA and/or to the fluorochrome Atto647N for detection. 
All nanocarriers were thoroughly characterized prior to use as 
recently described (27).
Mice
A 8- to 12-week-old female BALB/c and DO11.10 T  cell 
receptor-transgenic mice on a BALB/c background were bred 
specific pathogen-free at the Department of Clinical Research, 
University of Bern (Bern, Switzerland). Animal work was car-
ried out in accordance with the Swiss Federal Veterinary Office 
guidelines and was approved by the Cantonal Ethical Committee 
for Animal Experiments (Amt für Landwirtschaft und Natur 
des Kantons Bern) under animal experimentation permission 
number BE71/15.
intranasal administration and  
cell Preparation
BALB/c mice were deeply anesthetized for intranasal administra-
tion. One hundred (100) microliter total volume of either PBS, 
virosomes, or liposomes coupled to OVA or DQ-OVA (3  µg 
total), or empty virosomes or liposomes alone, or coadminis-
tered with soluble OVA or DQ-OVA (3  µg total) were applied 
via the nostrils. DQ-OVA was used for degradation and accu-
mulation assays as it consists of OVA bound to a self-quenching 
fluorescent dye, which upon intracellular degradation releases 
specific fluorescence (excitation at 505 nm, emission at 515 nm). 
Accumulated DQ-OVA forming dimers emit fluorescence in a 
different channel (excitation at 488  nm, emission at 613  nm). 
Animals were euthanized 24  h after intranasal administration 
and different lung compartments harvested for determining 
uptake, trafficking, phenotype and antigen degradation [trachea 
(T), lung parenchyma (LP), LDLNs, and broncho-alveolar lavage 
TaBle 1 | Particle characterization of virosomes and liposomes.
samples Dls nTa
size ± sD (nm) PDi ± sD size ± sD (nm)
Virosome-Atto647 95.1 ± 1.0 0.035 ± 0.004 76.9 ± 0.4
Virosome-Atto647-OVA 101.0 ± 5.8 0.041 ± 0.010 84.9 ± 0.5
Liposome-Atto647 92.6 ± 2.5 0.027 ± 0.002 79.1 ± 0.8
Liposome-Atto647-OVA 101.3 ± 8.4 0.025 ± 0.015 84.0 ± 0.4
Virosomes and liposomes coupled either to the fluorochrome Atto647 and/or model 
protein OVA were analyzed by dynamic light scattering (DLS; Zetasizer Nano S) or 
by nanoparticle tracking analysis (NTA; NanoSight NS300). Data represent three 
formulations of virosomes and liposomes with their average modal size (median ± SD, 
n = 3) and the polydispersity index (PDI).
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(BAL)], or for T  cell proliferation [non-draining lymph nodes 
(NDLNs) and LDLNs]. Single cell suspensions were prepared as 
described elsewhere (15, 16). Data for the different experimental 
groups were obtained from individual animals and at least five 
independent experiments are shown.
Flow cytometry
Digested cells were incubated on ice with FcR block for 10 min 
followed by viability staining with Fixable Viability Dye 
eFluor506 (eBioscience, Vienna, Austria) for 30  min on ice. 
Unless indicated otherwise, antibodies were purchased from 
eBioscience, and utilized with appropriate isotype controls: 
CD4-Brilliant Violet 785 (BioLegend, Lucerne, Switzerland), 
CD69-APC-eFluor 780, DO11.10-PE, CD11c-Brilliant Violet 
785 (BioLegend), CD11b-Alexa Fluor 700, MHCII-Brilliant 
Violet 711 (BioLegend), CD86-Brilliant Violet 605 (BioLegend), 
CD80-Brilliant Violet 605, CD40-PerCP-eFluor 710, CD8α-
PE-eFluor610, PD-L1-PE-Cy7 (BioLegend), PD-L2-FITC, and 
ICOS-L-PE. Intracellular cytokine staining was performed 
by using 20  µg/ml Brefeldin A (eBioscience) to stop protein 
transport. Subsequently, surface marker-stained cells were fixed 
in a 1% formalin solution followed by intracellular staining 
with the following antibodies with appropriate isotype control 
diluted in permeabilization buffer [PBS (Sigma) + 0.1% saponin 
(Sigma) + 10% FCS (Gibco; Thermo Fisher Scientific, Waltham, 
MA, USA)]: FoxP3-AlexaFluor 700, IL-4-PE-Cy7, IL-17A-Per-
CP-Cy5.5, IFNγ-eFluor450, and IL-9-eFluor660. Acquisition 
was performed by using a SORP LSRII (BD Biosciences) 
flow cytometer and data were analyzed by using FlowJo X 
software (Tree Star, Ashland, OR, USA) and FlowJo9 for T cell 
proliferation.
OVa-specific cD4+ T cell Proliferation  
in naïve BalB/c Mice
CD4+ T  cells from BALB/c DO11.10 mice were negatively 
selected using Dynabeads untouched mouse CD4 cell kit (Life 
Technologies, Grand Island, NY, USA). Cells were labeled with 
carboxyfluorescein succinimidyl ester (CFSE; eBioscience) and 
107 cells in 200  µl PBS were injected intravenously into naïve 
BALB/c mice. After 2  days, virosomes, liposomes, or PBS was 
administrated intranasally as described above. Three days later, 
LDLNs and NDLNs were collected and stained for surface markers 
and intracellular cytokines as mentioned above. Antigen-specific 
T cell proliferation (CFSE dilution) and cytokine production 
were measured by flow cytometry and analyzed with FlowJo9 
software (TreeStar).
statistics
Statistical analyses were conducted using R version 3.2.1 (28). 
All graphical representations were prepared using the R pack-
age ggplot2 (29). Differences in measured frequency and mean 
fluorescence intensity (MFI) between groups were tested using 
an ANOVA. Main and interaction effects of OVA (coupled vs 
soluble OVA) and treatment (liposome, virosome, and controls) 
were included in the model. Tukey’s honest significant dif-
ference post  hoc test was used to investigate individual paired 
comparisons. Appropriateness of ANOVA models was verified 
by residual analysis. No statistically significant difference was 
detected between “no OVA” (empty nanocarriers) and “coupled 
OVA” (nanocarriers with coupled OVA) for both virosomes 
and liposomes in uptake, viability, and phenotype experiments 
conducted. Therefore, we grouped data utilizing no OVA and 
coupled OVA virosomes and liposomes to perform the analyses 
as indicated.
resUlTs
Virosome and liposome characterization
Virosomes and liposomes were thoroughly characterized for 
size, homogeneity, particle amount, HA, and OVA content 
(Table 1) as previously described (27). Briefly, size and homo-
geneity were measured by dynamic light scattering and by 
nanoparticle tracking analysis (NTA), routinely providing a 
diameter of 90–100  nm. NTA analysis yielded approximately 
1E+13 particles/ml for all formulations. OVA and HA concen-
tration was determined by SDS-PAGE, Spotblot, and Western 
Blot, and HA concentrations were selectively reconfirmed by 
single radial immunodiffusion (data not shown). Both routinely 
yielded 50  µg/ml HA and 30  µg/ml OVA in the concentrated 
formulation. For intranasal administration, virosomes and 
liposomes were employed at a concentration of 3 µg/ml OVA. 
Limulus amebocyte lysate test of all concentrated formulations 
showed consistent results below 10.0  EU/ml for endotoxins 
(data not shown).
Uptake of inhaled Virosomes and 
liposomes by respiratory aPc subsets 
and Trafficking to lymph nodes
To detect in vivo uptake and trafficking of virosomes or liposomes 
by APCs situated in different respiratory tract compartments, 
we harvested T, LP, LDLN, and performed BAL 24  h after 
intranasal administration of virosomes, liposomes, or PBS 
control. We gated cells into CD11c+MHCIIlow macrophages, 
CD11c+MHCIIhighCD103−CD11b+ DCs (CD11b+ DCs), and 
CD11c+MHCIIhighCD103+CD11b− DCs (CD103+ DCs) (23, 30) 
(Figure S1 in Supplementary Material). As the number of DCs 
FigUre 1 | Uptake of virosomes (VirO) and liposomes (liPO) by cells in the respiratory tract. Liposomes and virosomes without OVA (“no OVA”) or with 
coupled OVA (“coupled OVA”) were intranasally administered and cells were analyzed for uptake 24 h later in broncho-alveolar lavage (BAL) fluid, trachea (T), lung 
parenchyma (LP), and lung-draining lymph nodes (LDLNs). Data represent frequency of uptake of five independent experiments. Statistical significance was 
determined by ANOVA followed by Tukey’s honest significant difference post hoc test to investigate individual paired comparisons.
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found in BAL was very low, the entire population, mostly CD11b+, 
was analyzed. In LDLNs, cells were subdivided into CD8α+ and 
CD8α−, representing resident and migratory DCs, respectively 
(30, 31). As virosomes and liposomes were suspended in a PBS 
pH 7.4 solution, we used PBS as uptake control solution (viro-
some and liposome data were calculated relative to PBS).
Our results showed that in BAL both virosomes and 
liposomes, with and without conjugated OVA, were taken up by 
macrophages and DCs alike, with more than 90% of cells being 
Atto+ (Figure  1). In the LDLN, there was low uptake of both 
nanocarriers for frequency and MFI (Figure  1; Figure S2 in 
Supplementary Material). Within the LP, macrophages, and to 
a lesser extent both subsets of DCs, captured particles, with no 
difference in uptake detected between virosomes and liposomes 
(Figure  1; Figure S2 in Supplementary Material). In the tra-
chea, neither CD11b+ nor CD103+ DCs captured virosomes 
or liposomes, whereas macrophages showed decent uptake of 
virosomes and liposomes uptake (Figure  1). In addition, in 
trachea macrophages also captured more particles per cell (based 
on MFI intensity) without discriminating between virosomes or 
liposomes (Figure S2 in Supplementary Material). We further 
systematically tested cell viability by using a viability dye suit-
able for detection by flow cytometry. No cell death was detected 
compared to PBS control for either virosomes or liposomes in 
any respiratory tract compartment (Figure S3 in Supplementary 
Material). In conclusion, virosomes and liposomes administered 
to the respiratory tract were captured most efficiently by mac-
rophages and DCs in BAL, macrophages in trachea and LP, and 
to a lesser extent DCs in the LP, with low extent of detectable 
trafficking of either particle to draining lymph nodes 24 h after 
intranasal administration.
antigen-specific T cell stimulation after 
exposure to Virosomes or liposomes
We next investigated whether particle-coupled or soluble OVA 
in combination with empty virosomes or liposomes as adjuvant/
nanocarrier would modulate downstream immune response by 
specifically activating CFSE-labeled, OVA-specific TCR trans-
genic CD4+ T cells as previously described (32). For this purpose, 
we intranasally administered either empty nanoparticles alone 
or together with soluble OVA, or nanoparticles coupled with 
OVA, 2 days after transgenic T cell transfer. Either PBS or PBS 
together with soluble OVA was employed as controls. As previ-
ously described (31), we utilized the FlowJo expansion index (EI) 
to determine proliferation based on the CFSE dilution profile 
(Figure S4 in Supplementary Material). The EI is the ratio of 
final cell count to starting cell count and therefore represents the 
fold of cellular expansion. OVA coupled to virosomes induced 
significantly enhanced CD4+ T  cell proliferation compared to 
virosomes alone (Figure 2A). Soluble OVA with nanoparticles or 
PBS induced an approximately twofold increase in EI compared 
to the no OVA control group. NDLN was used as internal negative 
control with no significant proliferation detected (Figure  2B). 
CFSE profiles demonstrated strong T  cell proliferation with 
OVA-coupled virosomes only (Figure 2C). Staining for intracel-
lular cytokines (IFN-γ, IL-17, IL-4, IL-9) and the Treg marker 
FoxP3 did not reveal any detectable polarization in vivo (Figure 
S5 in Supplementary Material). Taken together, these data show 
FigUre 2 | Measurement of antigen-specific cD4+ T cell proliferation by flow cytometry. Carboxyfluorescein succinimidyl ester (CFSE)-labeled CD4+ 
T cells were injected intravenously in naïve BALB/c mice. After 24 h, virosomes (VIRO), liposomes (LIPO), or PBS was given intranasally. Then 72 h later, lung-
draining lymph nodes (LDLNs) (a) and non-draining lymph nodes (NDLNs) (B) were collected and stained for surface markers. Antigen-specific T cell proliferation 
(CFSE dilution) was measured by flow cytometry. Panels show the expansion index (EI) of CD4+ T cells of six independent experiments. Note the altered Y-axis 
range. Statistical significance was determined by ANOVA followed by Tukey’s honest significant difference post hoc test to investigate individual paired comparisons 
(**p < 0.01). (c) FACS gating strategy for T cell proliferation. Cell gating includes forward and sideward scatter for live cells followed by a CD4+ DO11.10+ gating. 
Double positive cells were analyzed for CFSE profiles in NDLN and LDLNs to calculate the EI.
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that only antigen coupled to virosomes is able to induce strong 
antigen-specific T cell response, compared to empty virosomes. 
Furthermore, we detected no unequivocal evidence of T  cell 
polarization with the markers employed.
Phenotypic changes of respiratory aPc 
subsets after exposure to Virosomes and 
liposomes
In a next step, we investigated whether stronger T  cell 
proliferation with OVA-coupled virosomes was due to DC 
activation in LDLN and whether uptake of nanocarriers 
induced phenotypic changes in respiratory tract macrophage 
and DC populations. Therefore, respiratory tract compart-
ments (T, LP, LDLN, BAL) were sampled 24 h after intranasal 
administration of particles and single cells were stained for 
the surface makers CD40, CD80, CD86, PD-L1, PD-L2, and 
ICOS-L. Live, single cells were gated as previously described 
and further subdivided into particle positive (particle+) 
and particle negative (particle−) cells based on the Atto 
fluorescence signal (Figure S1 in Supplementary Material). 
Without separate analysis of nanocarrier particle positive 
and negative cells, no phenotypic changes were detected in 
APC populations after nanocarrier administration (data not 
shown).
Interestingly, CD8α+ resident DCs in LDLN significantly 
upregulated most costimulatory markers after uptake of particles 
(Figure 3A, particle+ DCs), and significant changes in MFI for 
CD40, CD80, and ICOS-L for virosomes in CD8α+ cells occurred 
(Figure S6A in Supplementary Material). CD8α− migratory DCs 
in LDLN significantly upregulated CD40, PD-L1, and PD-L2 
(Figure  3B) and MFI was increased for CD40 (Figure S6B in 
Supplementary Material). Furthermore, a low but significant 
increase in CD40 expression frequency in both macrophages in 
BAL and trachea and CD11b+ DCs in LP occurred (Figure 4), 
but no changes were detectable for the MFI (Figure S7A in 
Supplementary Material). CD80 expression significantly 
increased upon uptake of particles in CD11b+ DC cell popula-
tions in LP for both frequency (Figure 5) and MFI (Figure S7B 
in Supplementary Material), whereas CD86 expression was 
increased after particle uptake for both macrophages and 
CD11b+ DCs in LP (Figure 6). A significantly higher proportion 
of CD103+ DC expressed PD-L1 in both trachea and LP whereas 
CD11b+ DCs upregulated PD-L1 in LP and BAL after particle 
uptake (Figure 7). Following particle uptake, CD11b+ DCs from 
BAL and LP showed greater expression of PD-L1, as did mac-
rophages and CD103+ in LP (MFI; Figure S7D in Supplementary 
Material). An increased proportion of PD-L2 positive cells was 
found in the CD11b+ DCs from LP, as well in CD103+ DCs from 
trachea and LP (Figure 8) following particle uptake, whereas for 
MFI we detected significant change for macrophages, CD11b+ 
and CD103+ cells in LP, and CD11b+ DCs in T (Figure S7E in 
Supplementary Material). Similarly, for ICOS-L upregulation, an 
enhanced proportion of cells was seen in particle-bearing mac-
rophages, CD11b+ and CD103+ DCs from LP (Figure 9), and an 
increased MFI in macrophages from BAL and DCs in LP (Figure 
S7F in Supplementary Material).
Our data therefore indicate that particle uptake was associ-
ated with phenotypic changes, regardless of whether liposomes 
or virosomes were administered. Taken together we could detect 
activation of DCs in LDLN (CD40, CD80, CD86, PD-L1, PD-L2), 
BAL (CD40, PD-L1), trachea (CD40, PD-L1, PD-L2), and LP 
(CD40, CD80, CD86, PD-L1, PD-L2, ICOS-L), yet with no dif-
ferences seen between liposomes and virosomes.
antigen Degradation by aPcs after 
exposure to Virosomes and liposomes
In a next step, we measured whether uptake of nanocarriers 
was associated with alterations in antigen processing in APC 
subsets. For this analysis, DQ-OVA was coupled to virosomes 
and liposomes, or administered in its soluble form simultane-
ously with empty nanocarriers intranasally. DQ-OVA consists 
of OVA bound to a self-quenching fluorescent dye, which upon 
intracellular degradation releases specific fluorescence (excita-
tion at 505 nm, emission at 515 nm). Accumulated DQ-OVA on 
the other hand, forms dimers between dyes and emits fluorescent 
signal in a different channel (excitation at 488 nm, emission at 
613  nm). Controls were performed with PBS alone or supple-
mented with soluble DQ-OVA to determine the possible adjuvant 
effect of virosomes or liposomes. In BAL, antigen degradation 
and accumulation was detectable both in macrophages and DCs, 
but with no significant differences seen between liposomes and 
virosomes (Figure 10). Overall we observed a low number of cells 
that degraded DQ-OVA with no difference detected between sol-
uble or coupled DQ-OVA (Figure S8 in Supplementary Material) 
and antigen accumulation was very low in other respiratory tract 
compartments (Figure S9 in Supplementary Material).
DiscUssiOn
The ease of access of the respiratory tract makes it an attractive 
target organ for the administration of immunomodulatory 
biomimetic antigen nanocarriers. These may elicit their effects 
through interactions with a tightly enmeshed network of DCs 
that will capture and traffic nanocarriers to regional lymph 
nodes for specific T cell activation. Pulmonary administration 
of biomimetic nanoparticles such as virosomes or liposomes 
coupled to antigen may therefore represent a novel effective 
strategy to directly modulate adaptive immune responses in the 
respiratory tract. Virosomes not only serve as antigen carriers 
but are also endowed with intrinsic immune-stimulatory prop-
erties, as virosomes themselves are able to activate APCs and 
enhance uptake and processing of antigen (33, 34). Immune-
stimulatory properties derive from incorporated viral envelope 
proteins HA and NA, as recombinant influenza HA alone is able 
to induce DC activation (35–37). Activation of DCs by viro-
somes induced a Th1 type of cytokine profile (34). Additionally, 
surface features of virosomes are indistinguishable from those 
of the parental virus they derive from. Repetitive patterns of 
such viral surface structures render virosomes highly immuno-
genic by mimicking damage-associated molecular patterns and 
PAMPs, eventually activating DCs through interaction with 
PRR (38–40).
FigUre 3 | expression of surface markers in dendritic cells (Dcs) in lung-draining lymph nodes (lDlns) upon uptake of liposomes (liPO) and 
virosomes (VirO). LDLNs were harvested 24 h after intranasal administration of empty liposomes or virosomes (“no OVA”) or with liposomes and virosomes 
coupled to OVA (“coupled OVA”) or PBS control (not shown). Particle negative (particle−) and particle positive (particle+) cell populations were analyzed for expression 
of surface markers CD40, CD80, CD86, PD-L1, PD-L2, and ICOS-L and measured by flow cytometry. Data show frequency (%) of expression of CD8α+ resident  
(a) and CD8α− migratory DCs (B) and represent five independent experiments. Statistical significance was determined by ANOVA followed by Tukey’s honest 
significant difference post hoc test to investigate individual paired comparisons. *p < 0.05; **p < 0.01; ***p < 0.001.
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FigUre 4 | expression of surface marker cD40 in pulmonary antigen-presenting cells upon uptake of liposomes (liPO) and virosomes (VirO). Lung 
compartments (BAL, broncho-alveolar lavage; T, trachea; LP, lung parenchyma) were harvested 24 h after intranasal administration of empty liposomes or virosomes 
(“no OVA”) or with liposomes and virosomes coupled to OVA (“coupled OVA”) or PBS control (not shown). Particle negative (particle−) and particle positive (particle+) 
cell populations were analyzed for expression of surface marker CD40 measured by flow cytometry and frequency (%) is shown. Data represent five independent 
experiments. Statistical significance was determined by ANOVA followed by Tukey’s honest significant difference post hoc test to investigate individual paired 
comparisons (*p < 0.05; **p < 0.01; ***p < 0.001).
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There is still insufficient data available on the fate of virosomes 
and liposomes administered to the respiratory tract, as most 
clinical trials administered virosomes either intramuscular or 
intradermal. Virosomes delivered intranasally provided protec-
tion against influenza that was comparable to the intramuscular 
application (36, 37). Additionally, virosomes provided both a 
systemic and mucosal immune response upon intranasal delivery 
of DNA as compared to the intradermal route of administration 
(41). In vivo intranasal administration of a RSV-derived virosome 
vaccine induced high antibody titers and provided complete 
protection from RSV infection (42). Virosomes derived from 
respiratory viruses such as influenza and RSV may not only offer 
protective immunity but may potentially also provide a novel 
strategy for therapeutic immune modulation in the respira-
tory tract. In this study, we investigated the interaction of such 
nanocarriers with APCs in the respiratory tract, using an in vivo 
model to analyze uptake, phenotype and antigen processing 
capacity by macrophages, and DCs in different respiratory tract 
compartments. We also measured in vivo antigen-specific T cell 
stimulation by virosome- and liposome-bound antigen. Though 
our data show that both virosomes and liposomes are internalized 
by DCs, inducing their activation, only virosome-bound antigen 
generated a robust-specific CD4+ T cell proliferation in draining 
lymph nodes.
In the current study, both virosomes and liposomes were 
captured by respiratory tract APCs, but the extent of uptake 
depended on localization of APCs within the respiratory tract 
compartments. APCs in the alveolar space (BAL), through their 
prolonged interaction, were highly positive for the administered 
nanocarriers. Though tracheal APCs are an initial cell popula-
tion to encounter virosomes and liposomes, the exposure is 
limited since particulate antigen deposited in larger airways is 
rapidly cleared by the mucociliary escalator. This contrasts with 
the clearance in the alveolar gas-exchange regions, where clear-
ance by alveolar macrophages can take up to 24 h (43). Persistent 
antigen in the alveolar space due to slower clearance may 
FigUre 5 | expression of surface marker cD80 in pulmonary antigen-presenting cells upon uptake of liposomes (liPO) and virosomes (VirO). 
Lung compartments (BAL, broncho-alveolar lavage; T, trachea; LP, lung parenchyma; LDLN, lung-draining lymph nodes) were harvested 24 h after intranasal 
administration of empty liposomes or virosomes (“no OVA”) or with liposomes and virosomes coupled to OVA (“coupled OVA”) or PBS control (not shown). Particle 
negative (particle−) and particle positive (particle+) cell populations were analyzed for expression of surface marker CD80 measured by flow cytometry and frequency 
(%) is shown. Data represent five independent experiments. Statistical significance was determined by ANOVA followed by Tukey’s honest significant difference 
post hoc test to investigate individual paired comparisons (***p < 0.001).
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explain the stronger and most consistent uptake signal detected 
in this compartment. By contrast, the levels of virosomes and 
liposomes were very low 24 h after intranasal delivery, the opti-
mal time point for active delivery of inhaled antigens to DLN. 
By differential staining for CD8α, we were able to distinguish 
active transport from the airways by CD8α− DC from passive 
drainage to the LDLN and uptake by CD8α+ DCs. Migratory 
CD8α− DCs traffic antigen to LDLN, inducing antigen-specific 
T cell activation (44). By contrast, antigen that passively drains 
to the LDLN is primarily taken up by resident CD8α+ DCs. Due 
to low cell numbers and low particle signal obtained from lymph 
node cell suspensions, and the technically demanding FACS 
analysis, we failed to detect measureable levels of either soluble 
or coupled OVA that had drained to the LDLN or was actively 
transported by migrating DCs. The reason for this is unclear, 
but presumably relates to the preferential targeting of particles 
to non-migratory macrophages in the airways and LP. Our group 
previously showed that different types of particles delivered 
via the pulmonary route are primarily taken up by alveolar 
macrophages (31, 32), a finding which we also confirmed for 
both virosomes and liposomes. Alveolar macrophages are the 
first line of defense and hence play an important role in clearing 
apoptotic cells, debris as well as inhaled pathogens and particles 
to maintain lung homeostasis (45, 46). Contrary to DCs, lung 
macrophages are unable to efficiently stimulate T cells, and they 
do not migrate to local draining lymph nodes following antigen 
uptake. Enhanced uptake of particles by alveolar macrophages 
compared to pulmonary DC has also been shown by Jakubzick 
et al. (47). In this study, naïve C57BL/6 mice were instilled intra-
nasally with 500 nm polystyrene particles. In accordance with 
our findings, the majority of particles were found inside alveolar 
macrophages with very few particles transported to the LDLNs 
by pulmonary DCs 2 days after instillation. However, when mac-
rophages were depleted with clodronate integrated in liposomes, 
markedly greater numbers of DCs were recruited into the alveo-
lar space and particle transport to the LDLNs was boosted by 
FigUre 6 | expression of surface marker cD86 in pulmonary antigen-presenting cells upon uptake of liposomes (liPO) and virosomes (VirO). 
Lung compartments (BAL, broncho-alveolar lavage; T, trachea; LP, lung parenchyma; LDLN, lung-draining lymph nodes) were harvested 24 h after intranasal 
administration of empty liposomes or virosomes (“no OVA”) or with liposomes and virosomes coupled to OVA (“coupled OVA”) or PBS control (not shown). Particle 
negative (particle−) and particle positive (particle+) cell populations were analyzed for expression of surface marker CD86 measured by flow cytometry and frequency 
(%) is shown. Data represent five independent experiments. Statistical significance was determined by ANOVA followed by Tukey’s honest significant difference 
post hoc test to investigate individual paired comparisons (*p < 0.05; **p < 0.01).
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around 20-fold. The authors concluded a macrophage-mediated 
suppression of airway DC function by the modulation of DC 
recruitment to the airways. Pulmonary DCs offer an ideal target 
to modulate adaptive immune responses (30, 48). Enhanced tar-
geting of DCs in the respiratory tract may be achieved by binding 
of DC-specific ligands such as anti-DEC205 or anti-DC-SIGN 
onto the lipid bilayer (49, 50). Also, previous studies showed 
that liposomes bound to IgG increased binding and uptake 
by DCs via FcγR (51). Virosomes and liposomes may also be 
modified by either coupling antigen of interest onto the surface 
or incorporating it into the lumen (52). For example, a “self ” 
recognition peptide of CD47, when coupled to nanoparticles, 
was recently shown to avoid phagocytosis by macrophages as it 
is recognized as self, therefore prolonging nanoparticle circula-
tion and hence the duration for drug delivery (53). Combining 
CD47 and a DC-specific ligand on virosomes or liposomes may 
potentially increase uptake by DCs and reduce phagocytosis by 
macrophages.
Though we detected only a weak signal of particle+ DCs 
in LDLN, OVA-coupled virosomes generated a significantly 
increased naïve OVA-specific CD4+ T cell proliferation. Soluble 
OVA in combination with liposomes, virosomes, or PBS gener-
ated approximately a twofold increase of CD4+ T cell prolifera-
tion. Virosome-coupled antigen induced a significant increase of 
CD4+ T  cell proliferation at a low OVA concentration (3  µg 
total), compared to previous results in our group using gold 
or polystyrene particles where 50  µg of OVA was necessary to 
induce a comparable CD4+ T cell response (31, 32). This is also in 
line with a previous study, showing that a dose as low as 0.75 µg 
antigen (OVA) in combination with virosomes induced a strong 
cytotoxic T cell (CTL) response in vivo following intramuscular, 
intraperitoneal, or subcutaneous injection (18), contrasting with 
other two studies reporting that between 30 and 130 times more 
OVA is required to induce CTL when using liposomes (54). 
More importantly, successful T and B cell stimulation with low 
doses of peptides associated virosomes was also demonstrated 
FigUre 7 | expression of surface marker PD-l1 in pulmonary antigen-presenting cells upon uptake of liposomes (liPO) and virosomes (VirO). 
Lung compartments (BAL, broncho-alveolar lavage; T, trachea; LP, lung parenchyma; LDLN, lung-draining lymph nodes) were harvested 24 h after intranasal 
administration of empty liposomes or virosomes (“no OVA”) or with liposomes and virosomes coupled to OVA (“coupled OVA”) or PBS control (not shown). Particle 
negative (particle−) and particle positive (particle+) cell populations were analyzed for expression of surface marker PD-L1 measured by flow cytometry and frequency 
(%) is shown. Data represent five independent experiments. Statistical significance was determined by ANOVA followed by Tukey’s honest significant difference 
post hoc test to investigate individual paired comparisons (*p < 0.05; ***p < 0.001).
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in clinical studies (55, 56). These findings show that virosomes 
function both as an antigen carrier and adjuvant when applied 
systemically, and we have demonstrated a similar effect when 
virosomes were delivered locally to the lungs. Enhanced T cell 
responses to virosome-coupled antigen may first be due to 
the intact particulate characteristic of the antigen–virosome 
complex. As an example, employing gold nanoparticles coated 
with an aminated polymer shell, we have previously shown that 
only the particle–shell complex, but not the polymer alone was 
able to induce enhanced OVA-specific T  cell proliferation in 
BALB/c mice (32). Second, the combination of the antigenic 
viral compounds HA and NA may modulate antigen presenta-
tion in the LDLN. The virosome surface is responsible for a 
stronger immune stimulation, probably due to the addition of 
HA and NA, generating not only OVA-specific T cells but also 
HA-specific ones and therefore enhancing the overall immune 
response. Pre-existing immunity to influenza virus has no 
negative effects in humans (57, 58) but shows to be an advantage 
as both antigen-specific and influenza-specific T helper cells 
stimulate B cells and CTLs for strong immune response (34, 59). 
Mouse studies revealed that immunization with influenza virus 
resulted in higher antibody titers when administered with viro-
somes as adjuvants (60).
To investigate why only OVA-coupled virosomes induce strong 
and specific T cell response, we stained lung APCs for different 
surface markers and analyzed phenotype and costimulation 
marker expression by flow cytometry. Enhanced surface expres-
sion of costimulatory molecules like CD40, CD80, and CD86 is 
essential for induction of a strong and specific T  cell response 
(61). Therefore, we measured expression levels of these markers 
and in addition investigated the expression of PD-L1, PD-L2, and 
ICOS-L, interesting targets for induction of tolerance (62, 63). 
PD-L1 and PD-L2 are both ligands for programmed death-1 
(PD-1), expressed on activated T cells regulating T cell activation 
and tolerance. However, PD-L1 and PD-L2 expression remains 
controversial, as they can have both stimulatory and inhibitory 
FigUre 8 | expression of surface marker PD-l2 in pulmonary antigen-presenting cells upon uptake of liposomes (liPO) and virosomes (VirO). 
Lung compartments (BAL, broncho-alveolar lavage; T, trachea; LP, lung parenchyma; LDLN, lung-draining lymph nodes) were harvested 24 h after intranasal 
administration of empty liposomes or virosomes (“no OVA”) or with liposomes and virosomes coupled to OVA (“coupled OVA”) or PBS control (not shown). Particle 
negative (particle−) and particle positive (particle+) cell populations were analyzed for expression of surface marker PD-L2 measured by flow cytometry and frequency 
(%) is shown. Data represent five independent experiments. Statistical significance was determined by ANOVA followed by Tukey’s honest significant difference 
post hoc test to investigate individual paired comparisons (**p < 0.01; ***p < 0.001).
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effects on T  cells (64–67), as was seen in studies using OVA-
specific T  cell proliferation assays showing that overexpression 
or blocking of either of these two ligands interfered with T cell 
activation and proliferation (64, 68). Others found that block-
ing PD-L1 and PD-L2 resulted in increased T cell proliferation 
(69–71). In allergic diseases like asthma, the role of PD-L1 and 
PD-L2 is also still unclear as it was shown that both ligands have 
opposing roles in the regulation of airway hyperreactivity (AHR) 
(63). Akbari et al. demonstrated that PD-L2-knockout mice had 
increased AHR and inflammation (72), which was confirmed by 
a study that blocked PD-L2 during antigen challenge inducing 
increased AHR (73, 74). On the other hand, it was shown that 
PD-L1 deficiency had a positive effect on AHR and inflamma-
tion (63). A recent study performed by McAlees et al., however, 
showed that blocking the PD-L1/PD-1 pathway in an allergic 
asthma mouse model resulted in enhanced AHR by induction 
of Th17 cells in a mild AHR animal model (75). The inducible 
costimulatory ligand, ICOS-L, was also shown to play a role in 
an experimental asthma model as ICOS-deficient mice showed 
decreased Th2 response (76, 77) and ICOS–ICOS-L proved to be 
essential for the induction of T regulatory cells (78). In allergic 
rhinitis and asthma patients, it was demonstrated that ICOS-L 
expression on mDCs is impaired, contributing to the Th2-type 
immune response (79).
In our study, we observed phenotypic changes of DCs only 
in particle-bearing (particle+) cell populations, indicating that 
uptake of particles is essential for upregulation of phenotypic 
markers in DCs, but not in macrophages. Specifically, we 
observed upregulation of classical costimulatory markers 
such as CD40, CD80, and CD86 on both macrophages and 
DCs, indicating a moderate activation of DCs enabling 
T cell stimulation. On the other hand, we also observed even 
stronger upregulation of PD-L1 and PD-L2 in macrophages 
and DCs, which, as already stated, can have different effects 
on the polarization and tolerogenic state of T  cells. ICOS-L 
is enhanced in LP macrophages and DCs alike, indicating a 
FigUre 9 | expression of surface marker icOs-l in pulmonary antigen-presenting cells upon uptake of liposomes (liPO) and virosomes (VirO). 
Lung compartments (BAL, broncho-alveolar lavage; T, trachea; LP, lung parenchyma; LDLN, lung-draining lymph nodes) were harvested 24 h after intranasal 
administration of empty liposomes or virosomes (“no OVA”) or with liposomes and virosomes coupled to OVA (“coupled OVA”) or PBS control (not shown). Particle 
negative (particle−) and particle positive (particle+) cell populations were analyzed for expression of surface marker ICOS-L measured by flow cytometry and 
frequency (%) is shown. Data represent five independent experiments. Statistical significance was determined by ANOVA followed by Tukey’s honest significant 
difference post hoc test to investigate individual paired comparisons (*p < 0.05; ***p < 0.001).
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potential for strong T  cell stimulation and polarization away 
from Th2, as mentioned previously. Overall, this indicates that 
particle uptake is associated with DC activation and small 
amounts of particles were sufficient to trigger measurable 
phenotypic changes. From these data, we conclude that uptake 
of both virosomes and liposomes activated DCs, but the degree 
of activation primarily depended on the anatomical location, 
a finding that is consistent with previous data from our group 
obtained from in  vivo studies using gold nanoparticles that 
showed CD40 and CD86 upregulation upon particle uptake 
(32). Differences in the degree of activation seen in CD103+ 
and CD11b+ DCs may be explained by the fact that both 
subsets have distinct functional properties (80), with CD103+ 
DCs localized along the airways that are able to extend their 
dendrites through the epithelial tight junctions and therefore 
sample inhaled antigen from the airway lumen (23, 81). 
Additionally, it is known that this cell type is able to cross-
present antigen to CD8+ T cells (81–83). CD11b+ DCs on the 
other hand are assumed to be located mostly in the submucosa 
of the conducting airways and therefore only sample antigen 
that has crossed the epithelial layer. In our study, we did not 
detect any differences in uptake between these two DC subsets, 
possibly indicating similar access and uptake of virosomes and 
liposomes from the airway lumen and the submucosa.
To understand whether uptake of OVA-coupled virosomes 
or liposomes induced functional changes in macrophages and 
DCs, we measured the capacity of DCs to degrade coupled or 
soluble antigen. Self-quenching DQ-OVA was coupled to either 
virosomes or liposomes, or administered soluble together with 
empty particles. No difference in antigen degradation occurred 
between virosomes or liposomes, delivering either coupled or 
soluble DQ-OVA. The strongest degradation and accumulation 
signal was detected in BAL macrophages and DCs that paralleled 
the strong uptake of nanoparticles seen in cell populations of 
this compartment. Despite comparable antigen degradation and 
activation seen after treatment with OVA-coupled liposomes 
FigUre 10 | antigen degradation and accumulation in Bal. BAL was collected 24 h after intranasal administration of empty liposomes, virosomes, or PBS 
with soluble DQ-OVA (“soluble DQ-OVA”) or with liposomes and virosomes coupled to DQ-OVA (“coupled DQ-OVA”). Antigen degradation (a) and accumulation  
(B) was analyzed by measuring released fluorochrome signal from self-quenching DQ-OVA by flow cytometry. Panels show frequency (%) and MFI of six 
independent experiments. Statistical significance was determined by ANOVA followed by Tukey’s honest significant difference post hoc test to investigate individual 
paired comparisons.
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or soluble OVA co-administered with empty virosomes or 
liposomes, no significant increase in CD4+ T  cell proliferation 
compared to empty virosomes or liposomes was observed in 
these experimental groups.
To our knowledge, these findings are unique, showing that 
very low antigen concentrations bound to virosomes and 
administered to the respiratory tract are sufficient to generate a 
robust antigen-specific CD4+ T cell response in LDLN. This may 
have consequences if the pulmonary route is utilized for novel 
vaccination strategies, as concentration of virosome-bound 
antigen may be kept to a minimum, yet still generate a robust 
adaptive immune response. Though several studies showed a 
Th1 polarization after virosome stimulation (34, 84, 85), this 
did not occur in our in vivo model. Specifically targeting DCs 
to modulate CD4+ T  cell responses may represent a promis-
ing approach to treat allergic asthma where an enhanced Th2 
response frequently leads to IgE production (IL-4), eosinophilia 
(IL-5), mast cell activation (IL-9), and AHR (IL-13) (86, 87). 
Specific immune therapy, either subcutaneous or sublingual, 
is available for selected patients, but treatments last several 
years and are of variable efficacy (88–90). Pulmonary admin-
istered virosome-bound low-dose antigen may overcome such 
limitations with its potential to specifically modulate innate 
CD4+-dependent immune responses, without causing exces-
sive inflammatory responses that may jeopardize vital gaseous 
exchange in the lung.
In summary, we have demonstrated that intranasally 
administered virosomes and liposomes are taken up by 
macrophages and DCs in the respiratory tract and induce 
DC activation. There was no detectable difference in antigen 
processing or accumulation, but only OVA-coupled virosomes 
generated a specific and robust CD4+ T cell activation not seen 
with OVA-coupled liposomes or soluble OVA co-administered 
with virosomes or liposomes. Pulmonary administered 
antigen-bound virosomes may therefore provide an attractive 
approach to specifically and safely modulate adaptive immune 
responses in the respiratory tract, either to generate a protective 
immunity through vaccination, or as an approach for immune 
therapy in allergic asthma.
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